JP2022523196A - Ｆｌｎａ結合化合物及びその塩酸塩の固体多形 - Google Patents

Ｆｌｎａ結合化合物及びその塩酸塩の固体多形 Download PDF

Info

Publication number
JP2022523196A
JP2022523196A JP2021549470A JP2021549470A JP2022523196A JP 2022523196 A JP2022523196 A JP 2022523196A JP 2021549470 A JP2021549470 A JP 2021549470A JP 2021549470 A JP2021549470 A JP 2021549470A JP 2022523196 A JP2022523196 A JP 2022523196A
Authority
JP
Japan
Prior art keywords
crystalline
methyl
triazaspiro
decane
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523196A5 (https=
Inventor
マイケル ザムルート
リンジィ バーンズ バービアー
ショーン アンソニー クセラ
Original Assignee
ペイン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペイン セラピューティクス インコーポレイテッド filed Critical ペイン セラピューティクス インコーポレイテッド
Publication of JP2022523196A publication Critical patent/JP2022523196A/ja
Publication of JP2022523196A5 publication Critical patent/JP2022523196A5/ja
Priority to JP2024005868A priority Critical patent/JP2024054139A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021549470A 2019-02-21 2020-02-21 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形 Pending JP2022523196A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005868A JP2024054139A (ja) 2019-02-21 2024-01-18 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808609P 2019-02-21 2019-02-21
US62/808,609 2019-02-21
PCT/US2020/019305 WO2020172584A1 (en) 2019-02-21 2020-02-21 Solid polymorphs of a flna-binding compound and its hydrochloride salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005868A Division JP2024054139A (ja) 2019-02-21 2024-01-18 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形

Publications (2)

Publication Number Publication Date
JP2022523196A true JP2022523196A (ja) 2022-04-21
JP2022523196A5 JP2022523196A5 (https=) 2023-02-07

Family

ID=72141575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549470A Pending JP2022523196A (ja) 2019-02-21 2020-02-21 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形
JP2024005868A Pending JP2024054139A (ja) 2019-02-21 2024-01-18 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005868A Pending JP2024054139A (ja) 2019-02-21 2024-01-18 Ｆｌｎａ結合化合物及びその塩酸塩の固体多形

Country Status (10)

Country Link
US (4) US11370791B2 (https=)
EP (1) EP3927707A4 (https=)
JP (2) JP2022523196A (https=)
KR (1) KR20210135530A (https=)
CN (2) CN114072406B (https=)
AU (1) AU2020224678B2 (https=)
BR (1) BR112021016622A2 (https=)
CA (1) CA3131146A1 (https=)
IL (1) IL285763A (https=)
WO (1) WO2020172584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts
US20220233512A1 (en) * 2020-11-03 2022-07-28 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US9340558B2 (en) * 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
EP2549873A1 (en) * 2010-03-25 2013-01-30 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
EP2882428B1 (en) * 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
US9433604B2 (en) * 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005154234 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6015027444, 20 September 2002 (2002-09-20), pages 273 - 278, ISSN: 0005154233 *

Also Published As

Publication number Publication date
WO2020172584A1 (en) 2020-08-27
US12391693B2 (en) 2025-08-19
AU2020224678A1 (en) 2021-09-16
US20240400566A1 (en) 2024-12-05
JP2024054139A (ja) 2024-04-16
US20220340574A1 (en) 2022-10-27
CN114072406B (zh) 2025-03-18
EP3927707A4 (en) 2022-11-09
US12065440B2 (en) 2024-08-20
US11370791B2 (en) 2022-06-28
US20200270250A1 (en) 2020-08-27
CN114072406A (zh) 2022-02-18
CN120004896A (zh) 2025-05-16
AU2020224678B2 (en) 2024-03-14
NZ779310A (en) 2024-01-26
BR112021016622A2 (pt) 2021-11-03
IL285763A (en) 2021-10-31
EP3927707A1 (en) 2021-12-29
KR20210135530A (ko) 2021-11-15
CA3131146A1 (en) 2020-08-27
US20250084083A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US20200277266A1 (en) Solid state forms of trisodium valsartan: sacubitril
US20240083902A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US10023566B2 (en) Dasatinib salts
US12391693B2 (en) Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
JP2012522803A (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
EP3672968A1 (en) Ribociclib salts and solid state forms thereof
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
US20250179048A1 (en) Polymorphs of [2-(1h-indol-3-yl)-1h-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and its salts
JP2025148406A (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
CN115916751A (zh) S-吲哚洛尔的有机酸加成盐
US11136332B2 (en) Morphic forms of marizomib and uses thereof
JP2021533111A (ja) Ｌｔａ４ｈ阻害剤の結晶形態
WO2026072992A1 (en) Salts and solid forms of muscarinic receptor agonists
WO2017029408A1 (en) Solid state forms of sofosbuvir
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
WO2020154581A1 (en) Solid state forms of fedovapagon-salicyclic acid co-crystal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230130

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323